Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.

Hossein Borghaei; David M. O'Malley; Shelly Marie Seward; Todd Michael Bauer; Raymond P. Perez; Amit M. Oza; Woondong Jeong; Mary F. Michenzie; Maurice William Kirby; Gurudatt Chandorkar; Rodrigo Ruiz-Soto; Michael J. Birrer; Kathleen N. Moore

doi:10.1200/jco.2015.33.15_suppl.5558

Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5558 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5558-5558 ◽

Cited By ~ 8

Author(s):

Hossein Borghaei ◽

David M. O'Malley ◽

Shelly Marie Seward ◽

Todd Michael Bauer ◽

Raymond P. Perez ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Solid Tumors ◽

Folate Receptor ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

10.1158/1538-7445.am2020-ct125 ◽

2020 ◽

Author(s):

R. Wendel Naumann ◽

Denise Uyar ◽

John W. Moroney ◽

Fadi S. Braiteh ◽

Russell J. Schilder ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Fallopian Tube ◽

Folate Receptor ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5571 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5571-5571 ◽

Cited By ~ 4

Author(s):

Kathleen N. Moore ◽

Joseph Ponte ◽

Patricia LoRusso ◽

Michael J. Birrer ◽

Todd Michael Bauer ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Solid Tumors ◽

Folate Receptor ◽

Clinical Activity ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Relationship Of ◽

Antibody Drug

Download Full-text

138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)

10.1136/ijgc-2020-igcs.119 ◽

2020 ◽

Author(s):

R Naumann ◽

F Braiteh ◽

J Diaz ◽

E Hamilton ◽

S Diab ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Dose Escalation ◽

Folate Receptor ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Dose Escalation Study ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.085 ◽

2018 ◽

Vol 149 ◽

pp. 38 ◽

Cited By ~ 10

Author(s):

U.A. Matulonis ◽

K.N. Moore ◽

L.P. Martin ◽

I.B. Vergote ◽

C.M. Castro ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Download Full-text

Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5518 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5518-5518 ◽

Cited By ~ 5

Author(s):

Kathleen N. Moore ◽

Lainie P. Martin ◽

Shelly Marie Seward ◽

Todd Michael Bauer ◽

David M. O'Malley ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Phase I Trial ◽

Folate Receptor ◽

Single Agent ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.08.015 ◽

2017 ◽

Vol 147 (2) ◽

pp. 402-407 ◽

Cited By ~ 24

Author(s):

Lainie P. Martin ◽

Jason A. Konner ◽

Kathleen N. Moore ◽

Shelly M. Seward ◽

Ursula A. Matulonis ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Cancer Patients ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

First-in-human Phase 1 Study of MORAb-202, An Antibody-drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-positive Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-4740 ◽

2021 ◽

pp. clincanres.4740.2020

Author(s):

Toshio Shimizu ◽

Yutaka Fujiwara ◽

Kan Yonemori ◽

Takafumi Koyama ◽

Jun Sato ◽

...

Keyword(s):

Solid Tumors ◽

Folate Receptor ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Eribulin Mesylate ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Abstract C47: Association of folate receptor alpha (FRα) expression level and clinical activity of IMGN853 (mirvetuximab soravtansine), a FRα-targeting antibody-drug conjugate (ADC), in FRα -expressing platinum-resistant epithelial ovarian cancer (EOC) patients (pts)

10.1158/1535-7163.targ-15-c47 ◽

2015 ◽

Cited By ~ 2

Author(s):

Lainie P. Martin ◽

Kathleen Moore ◽

David M. O'Malley ◽

Shelley Seward ◽

Todd M. Bauer ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Expression Level ◽

Clinical Activity ◽

Antibody Drug Conjugate ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Download Full-text

IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5567 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5567-5567 ◽

Cited By ~ 2

Author(s):

Kathleen N. Moore ◽

Lainie P. Martin ◽

Ursula A. Matulonis ◽

Jason A. Konner ◽

Shelly Marie Seward ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Single Agent ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Download Full-text

28LBA A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(16)31946-3 ◽

2015 ◽

Vol 51 ◽

pp. S724 ◽

Cited By ~ 2

Author(s):

A.W. Tolcher ◽

E. Calvo ◽

M.L. Maitland ◽

B. Gibson ◽

D. Xuan ◽

...

Keyword(s):

Solid Tumors ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text